T-MAXIMUM's B7-H3-Targeted Allogeneic CAR-T MT027 Receives FDA Clearance for Phase 2 Study in Brain Metastases from Lung and Breast Cancer
BEIJING, Oct. 12, 2026 /PRNewswire/ -- T-MAXIMUM PHARMACEUTICAL ("T-MAXIMUM") today announced that the U.S. Food and Drug Administration (FDA) has cleared the company to initiate a Phase 2 clinical study of MT027, its internally developed, B7-H3-targeted universal (allogeneic) CAR-T...
Covered in this story
What has happened since
- Universal Corp is down 4.9% since this was published, 8 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $UVV yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Universal Corp →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.